U.S. Leisure Stock News

NasdaqGS:CZR
NasdaqGS:CZRHospitality

Will Caesars’ Narrowed Loss and New Venues Reshape Caesars Entertainment's (CZR) Investment Narrative?

In the first quarter of 2026, Caesars Entertainment reported higher sales of US$2,153 million and revenue of US$2,870 million, while reducing its net loss to US$98 million compared with the prior year. Alongside these improved results, Caesars has been expanding its entertainment offerings with new venues such as OMNIA Dayclub & Skybar in Las Vegas and the upcoming Caesars Beach Club in Atlantic City, aiming to draw more visitors to its properties. Next, we will examine how Caesars’ narrowed...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Does Milestone-Driven Profit Shift the Bull Case For Protagonist Therapeutics’ New Model (PTGX)?

Protagonist Therapeutics reported first-quarter 2026 results that swung to a net income of US$3.78 million, helped by a US$50 million milestone payment linked to FDA approval of ICOTYDE and a US$200 million payment from restructuring its rusfertide collaboration. These developments not only produced an unexpected profit but also shifted Protagonist’s business model toward milestone- and royalty-based revenues backed by liquidity of about US$620.3 million. Next, we’ll examine how this move...
NasdaqGS:VRTX
NasdaqGS:VRTXBiotechs

Vertex’s German CASGEVY Deal And The Push Beyond Cystic Fibrosis

Vertex Pharmaceuticals (NasdaqGS:VRTX) has secured a reimbursement agreement in Germany for its CASGEVY gene therapy for sickle cell disease and beta thalassemia. This is Germany's first long term access deal for a gene edited therapy of this kind, supporting broader patient access within the country. The agreement expands CASGEVY access in Europe and adds to Vertex's efforts to build revenue beyond its cystic fibrosis portfolio. For investors tracking NasdaqGS:VRTX, the new German...
NYSE:CNC
NYSE:CNCHealthcare

How Strong Q1 2026 Results and Higher Guidance Will Impact Centene (CNC) Investors

In the first quarter of 2026, Centene Corporation reported revenue of US$49.94 billion and net income of US$1.54 billion, with diluted EPS from continuing operations of US$3.11, all higher than a year earlier. Alongside these results, Centene raised its 2026 guidance, lifting expected total revenue to between US$187.50 billion and US$191.50 billion and increasing its GAAP diluted EPS outlook to above US$2.37, signaling management’s confidence in ongoing margin and cost initiatives. We’ll now...
NYSE:MKL
NYSE:MKLInsurance

How Investors May Respond To Markel Group (MKL) Activist Push To Spin Off Ventures And Buy Back Stock

In late April 2026, JANA Partners sent a letter to Markel Group’s board urging a divestiture of Markel Ventures and a US$2.00 billion share repurchase tender, while questioning incentive payouts and arguing that the Ventures segment has diluted the value of the core insurance business. This activist push brings Markel’s long-standing “forever home” pledge to acquired businesses into direct tension with shareholder priorities around capital allocation and corporate structure. We’ll now...
NasdaqGS:VRNS
NasdaqGS:VRNSSoftware

Varonis Systems (VRNS) Is Up 9.0% After AI-Fueled Beat, Buyback Completion And Raised 2026 Outlook

In late April 2026, Varonis Systems reported first-quarter revenue of US$173.13 million, a similar loss per share as a year earlier, completed a US$149.99 million buyback program, and issued guidance calling for double-digit revenue growth for the second quarter and full year 2026. At the same time, Varonis highlighted surging demand for its AI and data security platform, including new ENS High certification in Spain and stronger SaaS adoption, reinforcing its role in securing the data that...
NYSE:VIK
NYSE:VIKHospitality

Viking Expands 2028–2029 Expeditions As Premium Growth Story Builds

Viking Holdings (NYSE:VIK) opened bookings for its expanded 2028–2029 expedition voyages. The company added new departure dates and extra sailings in the Arctic, Antarctica, and the Great Lakes. The move widens Viking's expedition footprint across remote and cold-weather destinations. Viking Holdings, listed as NYSE:VIK, focuses on premium cruises, including ocean, river, and expedition offerings. The decision to expand expedition sailings in 2028 and 2029 in the Arctic, Antarctica, and the...
NasdaqGS:ADBE
NasdaqGS:ADBESoftware

Is It Time To Reassess Adobe (ADBE) After Its Recent Share Price Slump?

If you are wondering whether Adobe's current share price really reflects what the stock could be worth, this breakdown will help you weigh up the numbers behind that question. Adobe closed at US$256.51, with returns of 4.2% over the last week and 6.8% over the last month, while the year-to-date return stands at a 23.0% decline and the 1-year return at a 33.2% decline. Recent moves in the stock sit alongside ongoing attention on Adobe's position in creative software and digital media, as...
NYSE:RKT
NYSE:RKTDiversified Financial

Rocket Companies (RKT) Swings To Q4 Profit And Tests Bullish Turnaround Narrative

Rocket Companies (RKT) closed FY 2025 with fourth quarter revenue of US$2.8b, basic EPS of US$0.02 and net income of US$68.0m, setting a clear marker for how the year wrapped up. Over recent periods the company has seen quarterly revenue move from US$1.9b in Q4 2024 to US$2.8b in Q4 2025, while basic EPS shifted from US$0.23 to US$0.02, and net income moved from US$33.5m to US$68.0m. This provides a clear view of how the top and bottom lines translated into current margins and overall...
NasdaqGM:INOD
NasdaqGM:INODProfessional Services

Innodata (INOD) Margin Compression Challenges Bullish AI Growth Narrative After FY 2025 Results

Innodata (INOD) just wrapped up FY 2025 with fourth quarter revenue of US$72.4 million and basic EPS of US$0.28, while trailing twelve month revenue came in at US$251.7 million and basic EPS at US$1.01. Over recent quarters the company has seen revenue move from US$59.2 million in Q4 2024 to US$72.4 million in Q4 2025, with basic EPS shifting from US$0.34 to US$0.28 over the same period. This sets up a picture where growth expectations and margin trends will be front of mind for investors...
NYSE:MRP
NYSE:MRPSpecialized REITs

Is It Time To Reassess Millrose Properties (MRP) After The Recent Share Price Pullback

If you are wondering whether Millrose Properties at around US$26.90 still offers value, the starting point is to understand what the current price implies about the business. The stock is up 14.1% over the last year, even though it has seen a 12.3% decline over the past week and a 3.0% decline over the past month, with a 9.8% decline year to date. This may have shifted how some investors think about its risk and reward trade off. Recent coverage has focused on Millrose Properties as a...
NasdaqGS:ARCB
NasdaqGS:ARCBTransportation

A Look At ArcBest (ARCB) Valuation After Q1 Earnings Shift To Net Loss And Management’s Shipment Growth Confidence

ArcBest (ARCB) stock was in focus after first quarter earnings showed sales of US$998.79 million and a net loss of US$1.04 million, with management highlighting stable demand despite winter weather and fuel headwinds. See our latest analysis for ArcBest. The Q1 update and ongoing buybacks have come against a backdrop of strong share price momentum, with a year to date share price return of 57.81% and a 1 year total shareholder return of 96.13%. The recent 7 day share price pullback of 4.54%...
NasdaqGS:CCEC
NasdaqGS:CCECShipping

Capital Clean Energy Carriers TTM Margin Surge Challenges Bearish Narratives On Profit Durability

Capital Clean Energy Carriers (CCEC) has just wrapped up FY 2025 with fourth quarter revenue of US$86.8 million and basic EPS of US$0.46. Trailing 12 month EPS came in at US$1.92 as earnings over that period were very large compared with the prior year. The company has seen revenue on a trailing 12 month basis move from US$339.5 million in FY 2024 to US$392.7 million in FY 2025. Over the same period, EPS shifted from US$0.13 to US$1.92 and net profit margin moved from 2.2% to 28.9%. These...
NYSE:GNW
NYSE:GNWInsurance

How Genworth’s Buybacks, Enact and CareScout Build-Out At Genworth Financial (GNW) Has Changed Its Investment Story

Genworth Financial reported past first-quarter 2026 results with revenue of US$1,777 million and net income of US$47 million, alongside modestly lower earnings per share year over year. The company also completed a sizeable share repurchase program and highlighted Enact’s contribution and the build-out of CareScout as key parts of its longer-term plan. Next, we will examine how Genworth’s continued share repurchases shape the company’s investment narrative and its appeal to different...
NYSE:GPGI
NYSE:GPGITech

A Look At GPGI’s Valuation After Q1 2026 Results And New International Leadership Appointment

GPGI (GPGI) is drawing fresh attention after first quarter 2026 results combined record sales at CompoSecure with a US$235 million net loss and weaker Husky performance, along with a new international commercial leadership appointment. See our latest analysis for GPGI. The first quarter loss and Husky headwinds have coincided with sharp share price weakness, with a 1 day share price return of negative 25.9% and a 90 day share price return of negative 47.1%. However, the 3 year total...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona (XRAY) Now Offering Value After A 28% One Year Share Price Slide

If you are wondering whether DENTSPLY SIRONA stock is starting to look interesting at current levels, its recent price and valuation signals give you a lot to think about. The share price sits at US$10.96 after a 6.7% decline over the last week, a 4.9% decline over the last month and a 28.5% decline over the last year, which may change how you view both its risk and potential reward. Recent coverage around DENTSPLY SIRONA has focused on its position within the medical equipment space and how...
NasdaqGS:RGEN
NasdaqGS:RGENLife Sciences

Assessing Repligen (RGEN) Valuation After Earnings Beat Guidance Raise And Portfolio Moves

Repligen (RGEN) is back in focus after its first quarter 2026 earnings, where profit topped market expectations, full year adjusted earnings guidance moved higher, and the stock gained 7.3% on the news. See our latest analysis for Repligen. Beyond the post earnings jump, Repligen’s 7 day share price return of 6.86% and 30 day share price return of 9.66% sit against a year to date share price decline of 23.07%. The 1 year total shareholder return of a 1.11% decline and 3 year total shareholder...
NYSE:CR
NYSE:CRMachinery

A Look At Crane (CR) Valuation After Q1 Beat Guidance Lift And Margin Pressure

What Crane’s latest earnings and M&A comments mean for investors Crane (CR) just paired a Q1 earnings beat with a slight uptick in full year adjusted EPS guidance, yet a softer operating margin and active acquisition agenda are shaping how investors reassess the stock. See our latest analysis for Crane. Crane’s recent Q1 earnings beat, slight full year EPS guidance increase, dividend affirmation, and active M&A commentary come after a 1 year total shareholder return of 7.6%. The 3 year total...
NYSE:CLH
NYSE:CLHCommercial Services

Is Clean Harbors (CLH) Turning PFAS Landfill Demand and AI Efficiencies Into Durable Profitability?

In early May 2026, Clean Harbors, Inc. reported first-quarter 2026 results showing revenue of US$1,459.54 million and net income of US$63.2 million, and issued full-year 2026 GAAP net income guidance of US$421 million to US$472 million. The quarter also featured record safety performance, strong landfill volume growth tied to PFAS and project work, and higher full-year adjusted EBITDA guidance supported by operational efficiency initiatives, including AI deployment and new field service...
NasdaqGS:FSLR
NasdaqGS:FSLRSemiconductor

First Solar (FSLR) Is Up 6.3% After Strong Q1 2026 Beat And Reaffirmed Outlook - What's Changed

In the first quarter of 2026, First Solar reported sales of US$1,044.24 million and net income of US$346.62 million, with basic earnings per share from continuing operations of US$3.23, all higher than a year earlier. Alongside these results, the company reaffirmed its 2026 outlook, including expected module volumes of 17.0–18.2 GW and net sales of US$4.90–US$5.20 billion, reinforcing visibility into its order book and manufacturing plans. Building on this earnings strength and reaffirmed...
NasdaqGS:SAIA
NasdaqGS:SAIATransportation

Assessing Whether Saia (SAIA) Still Offers Value After Strong Recent Share Price Gains

Why Saia (SAIA) is on investors’ radar right now Saia (SAIA) has drawn fresh attention after a recent share price move, with the stock showing strong trailing returns over the past year and past 3 months. This performance has prompted closer scrutiny of its fundamentals. See our latest analysis for Saia. Despite a small 1-day share price decline, Saia’s 30-day share price return of 19.52% and 1-year total shareholder return of 68.91% point to momentum building on top of its longer term...
NYSE:EHC
NYSE:EHCHealthcare

Encompass Health (EHC) Is Up 7.1% After Earnings Beat, Guidance Hike And Capital Return Update

In recent weeks, Encompass Health Corporation reported higher first‑quarter 2026 sales of US$1,586.6 million and net income of US$194.5 million, raised its full‑year net operating revenue guidance, continued share repurchases under its long‑running buyback, opened a new 50‑bed rehabilitation hospital in Concordville, Pennsylvania, and declared a quarterly dividend of US$0.19 per share payable on July 15, 2026. Together, the earnings beat, guidance increase, capacity expansion and ongoing...
NYSE:MRK
NYSE:MRKPharmaceuticals

Merck Faces Gardasil Trial As Oral PCSK9 Progress Reshapes Risk Profile

Merck (NYSE:MRK) faces an upcoming Gardasil vaccine safety trial scheduled for late July, focusing on product safety and potential liability claims. The company has also published new research on a large scale, enzyme enabled synthesis route for its oral PCSK9 inhibitor candidate. This synthesis work could help support development of what may become one of the first oral PCSK9 treatments for cholesterol management. Merck enters these developments with its stock at $112.3 and a return of...